Can Lung Deposition Data Act As a Surrogate for the Clinical Response to Inhaled Asthma Drugs?

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2000 Jun 10

PMID 10848716

Citations 8

Authors

S P Newman

Affiliations

Soon will be listed here.

Abstract

Studies involving the direct measurement of clinical response to inhaled asthma drugs, especially inhaled corticosteroids, may be very difficult to conduct. However, the deposition of drug in the lungs may be considered as a measure of local bioavailability, and may be quantified by radionuclide imaging techniques, or for some drugs by pharmacokinetic methods. This paper reviews evidence for considering lung deposition data as a surrogate for the clinical response to inhaled asthma drugs, based mainly upon a series of case histories. The appropriate use of lung deposition data in regulatory packages, especially to document the equivalence or comparability of two products, offers the possibility of significant time saving in the drug development process, and hence a faster drug development programme for inhaled asthma products.

Citing Articles

The effects of airway disease on the deposition of inhaled drugs.

Darquenne C, Corcoran T, Lavorini F, Sorano A, Usmani O Expert Opin Drug Deliv. 2024; 21(8):1175-1190.

PMID: 39136493 PMC: 11412782. DOI: 10.1080/17425247.2024.2392790.

Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations.

Miyamoto K, Akita T, Yamashita C Pharmaceutics. 2022; 14(4).

PMID: 35456593 PMC: 9033134. DOI: 10.3390/pharmaceutics14040759.

Risk for pneumonia requiring hospitalization or emergency room visit according to delivery device for inhaled corticosteroid/long-acting beta-agonist in patients with chronic airway diseases as real-world evidence.

Park J, Kim Y, Choi S, Jang E, Kim J, Lee C Sci Rep. 2019; 9(1):12004.

PMID: 31427602 PMC: 6700062. DOI: 10.1038/s41598-019-48355-2.

Continued Innovation in Respiratory Care: The Importance of Inhaler Devices.

Bosnic-Anticevich S Tuberc Respir Dis (Seoul). 2018; 81(2):91-98.

PMID: 29589381 PMC: 5874147. DOI: 10.4046/trd.2017.0119.

Mechanisms of pharmaceutical aerosol deposition in the respiratory tract.

Cheng Y AAPS PharmSciTech. 2014; 15(3):630-40.

PMID: 24563174 PMC: 4037474. DOI: 10.1208/s12249-014-0092-0.

References

Pauwels R, Newman S, Borgstrom L . Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur Respir J. 1997; 10(9):2127-38. DOI: 10.1183/09031936.97.10092127. View

Newman S, Millar A, Moren F, Clarke S . Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax. 1984; 39(12):935-41. PMC: 459957. DOI: 10.1136/thx.39.12.935. View

Newman , Wilding . Imaging techniques for assessing drug delivery in man. Pharm Sci Technol Today. 1999; 2(5):181-189. DOI: 10.1016/s1461-5347(99)00152-2. View

Newman S, Steed K, Reader S, Hooper G, Zierenberg B . Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996; 85(9):960-4. DOI: 10.1021/js950522q. View

Bondesson E, Friberg K, Soliman S, Lofdahl C . Safety and efficacy of a high cumulative dose of salbutamol inhaled via Turbuhaler or via a pressurized metered-dose inhaler in patients with asthma. Respir Med. 1998; 92(2):325-30. DOI: 10.1016/s0954-6111(98)90116-0. View

Messina M, Smaldone G . Evaluation of quantitative aerosol techniques for use in bronchoprovocation studies. J Allergy Clin Immunol. 1985; 75(2):252-7. DOI: 10.1016/0091-6749(85)90054-5. View

. Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy. J Biol Stand. 1989; 17(3):213-22. PMC: 7133254. DOI: 10.1016/0092-1157(89)90013-9. View

Hindle M, Chrystyn H . Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol. 1992; 34(4):311-5. PMC: 1381412. DOI: 10.1111/j.1365-2125.1992.tb05921.x. View

Howarth P . What is the nature of asthma and where are the therapeutic targets?. Respir Med. 1998; 91 Suppl A:2-8. DOI: 10.1016/s0954-6111(97)90096-2. View

10.

Nikander K . Drug delivery systems. J Aerosol Med. 1993; 7(Suppl 1):S19-24. DOI: 10.1089/jam.1994.7.suppl_1.s-19. View

11.

Borgstrom L . Deposition patterns with Turbuhaler. J Aerosol Med. 1993; 7(Suppl 1):S49-53. DOI: 10.1089/jam.1994.7.suppl_1.s-49. View

12.

Newman S, Steed K, Hooper G, Kallen A, Borgstrom L . Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res. 1995; 12(2):231-6. DOI: 10.1023/a:1016278926231. View

13.

Auty R, Brown K, Neale M, Snashall P . Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br J Dis Chest. 1987; 81(4):371-80. DOI: 10.1016/0007-0971(87)90186-0. View

14.

Newman S, Clarke S . Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest. 1993; 103(5):1442-6. DOI: 10.1378/chest.103.5.1442. View

15.

Davies R, Stampone P, OConnor B . Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med. 1998; 92 Suppl A:23-31. DOI: 10.1016/s0954-6111(98)90214-1. View

16.

Newman S, Steed K, Hooper G, Jones J, Upchurch F . Improved targeting of beclomethasone diproprionate (250 micrograms metered dose inhaler) to the lungs of asthmatics with the Spacehaler. Respir Med. 1999; 93(6):424-31. DOI: 10.1053/rmed.1999.0587. View

17.

Leach C, Davidson P, Boudreau R . Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1999; 12(6):1346-53. DOI: 10.1183/09031936.98.12061346. View

18.

Zainudin B, Biddiscombe M, Tolfree S, Short M, Spiro S . Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax. 1990; 45(6):469-73. PMC: 462532. DOI: 10.1136/thx.45.6.469. View

19.

Newman S . How well do in vitro particle size measurements predict drug delivery in vivo?. J Aerosol Med. 1997; 11 Suppl 1:S97-104. View

20.

Newnham D, McDevitt D, Lipworth B . Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol. 1993; 36(5):445-50. PMC: 1364617. DOI: 10.1111/j.1365-2125.1993.tb00393.x. View